Back to Results
First PageMeta Content
Belatacept / Transplantation medicine / Renal function / Kidney transplantation / Co-stimulation / Chronic kidney disease / Dialysis / Transplant rejection / Medicine / Bristol-Myers Squibb / T cells


TITLE PAGE Belatacept (BMS[removed]FDA’s Cardiovascular and Renal Drugs Advisory Committee
Add to Reading List

Open Document

File Size: 850,43 KB

Share Result on Facebook

Company

Bristol-Myers Squibb Company / Randomized Treatment Group / Bristol-Myers Squibb / /

Event

FDA Phase / /

Facility

Laboratory Findings / /

IndustryTerm

treatment for end-stage renal disease / /

MedicalCondition

onset diabetes / progressive renal dysfunction / Hypertension / Post-transplant Lymphoproliferative Disorder / First Serious Infection / interstitial fibrosis / Lymphoproliferative Disorder / Hypersensitivity / chronic allograft nephropathy / end-stage renal disease / Infections / Dyslipidemia / Malignant Neoplasms / Tuberculosis / /

MedicalTreatment

Renal transplantation / immunosuppression / immunosuppressive therapies / dialysis / renal transplant / /

Organization

FDA / Belatacept BMS-224818 IM103 Advisory Committee / /

Position

Briefing Document EXECUTIVE / /

Product

Cyclosporine / IM103008 / IM103 / IM103027 / Belatacept / BMS-224818 / /

ProvinceOrState

New Jersey / /

RadioStation

Core / /

Technology

Transplantation / dialysis / /

SocialTag